Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial

Shenglong Li a,*, Xixi Wu c,*, Peng Chen b, Yi Pe i a, Ke Zheng a, Wei Wang a, Enduo Qiu a and Xiaojing Zhang a

The US Food and Drug Association has approved interferon-α (IFN-α) and interleukin-2 (IL-2) as adjuvant therapy in malignant melanoma. The objective of the study was to compare efficacy and safety of subcutaneous interferon-α with continuous intravenous IL-2 in Chinese patients with malignant melanoma. A total of 250 patients with unresectable malignant melanoma were subjected to randomized in 1:1 ratio. Patients received subcutaneous $9 \times 10^6$ IU/m² IFN-α (IFN-α group, $n=125$) or continuous intravenous $9 \times 10^6$ IU/m² IL-2 (IL-2 group, $n=125$) at every 21 days for 4 months. The response, progression-free survival, overall survival, adverse effects, and cost were evaluated by experts in the field. IL-2 and IFN-α were effective in improvement of malignant melanoma after 4 months of intervention. IL-2 was effective in improving brain metastasis. Patients of the IL-2 group had a higher overall survival ($P<0.0001$) and a higher progression-free survival ($P=0.002$) than those of IFN-α group. The IL-2 group reported hypotension, kidney dysfunction, liver dysfunctions, flu-like symptoms, and capillary leak syndrome as adverse effects. IFN-α group reported thrombocytopenia and neutropenia as adverse effects.

Introduction

Malignant melanoma is a tumor of melanocytes in the skin [1]. Malignant melanoma rarely occurs (only 4%) in skin cancer [2]. Among all dermatologic cancers, 80% of cases are lethal [3]. Research prospectus and clinical efforts in the prognosis of advancement of the stage of malignant melanoma are poor. Its prognosis in Chinese patients is high (20 000 new cases/year) [4]. Therefore, the therapeutic management of malignant melanoma needs to be addressed soon as there are a large number of patients affected in People’s Republic of China.

Interferon-α (IFN-α) is mainly produced endogenously by macrophages and has proved anticancer effects in the experimental studies and the clinical trials [5]. It has improved overall survival and disease-free survival in patients with high-risk cutaneous melanoma [6], but the mechanism of action is unclear yet [7]. Treatment-emergent adverse effects are increased and cause a financial burden on patients when it is used with a chemotherapeutic agent(s) [6].

Interleukin-2 (IL-2) has complex biological effects and exerts an antitumor effect by enhancing cytotoxic T lymphocyte and natural killer cell lysis. Intravenously infused high dose of IL-2 (100–150 $\times 10^6$ IU/m²/day) is more toxic than low dose (10$^6$ IU/m²/day) [4,8]. Subcutaneous administration of IL-2 is less toxic than intravenous infusion [4]. Continuous infusion is more toxic than continuous dripping [4] and has capillary leak syndrome and flu-like symptoms as adverse effects [4]. However, it has higher efficacy for Chinese patients than US patients because Chinese patients get longer response duration than White patients because of changes in its pharmacokinetics in different populations [9].

Although the US Food and Drug Association has approved IFN-α and IL-2 as adjuvant therapy in malignant melanoma [4,10]. These forms of treatment have no guidelines associated with them in China, and the rationale for carrying out the study is to shed more light on the requirements of their inclusion.

The primary aim of the study was to treat Chinese patients with malignant melanoma using a high dose of
subcutaneous IFN-α or continuous intravenous IL-2 for 4 months. The secondary end point of the trial was to compare the efficacy and safety of IFN-α therapy with IL-2 therapy and to do the research that Chinese guidelines are inadequate when it comes to using of IFN-α as a cancer treatment.

**Patients and methods**

**Drugs**

IFN-α and IL-2 were purchased from Essex Pharma GmbH (Munich, Germany).

**Compliance with ethical standards**

The study had been registered in the Research registry (http://www.researchregistry.com), UID No. researchregistry4361, dated 9 January 2015. The protocol of the study (CMU/CL/03/15 dated 7 January 2015) had been approved by the Cancer Hospital of China Medical University Review Board. The study had adhered to the law of China, consolidated standards of reporting trials (CONSORT) [11], and Declaration of Helsinki (V2008) [12]. An informed consent form with regard to interventions, pathology, and publications of the study including personal data and images in all formats (hard and/or electronic) irrespective to time and language had been signed by patients and their relatives (legally authorized persons).

**Inclusion criteria**

All patients age 18 years and above with histologically confirmed and unresectable malignant melanoma, admitted to the Cancer Hospital of China Medical University (Shenyang, China), and the referring hospitals from 13 January 2015 to 1 December 2017 were included in the trial. Patients with Eastern Cooperative Oncology Group performance status (0–5 scale, with regard to disease progression, where 0: fully active patient and 5: dead [13]) score of 2 or less were included in the study. Patients who had adequate functioning of vital organs (kidney, heart, brain, lungs, and liver) were included in the study. Patients who had not signed an informed consent form were also excluded from the trial.

**Exclusion criteria**

Patients who have received steroids and had forced expiratory volume less than 75% were excluded from the study. Patients who had not signed an informed consent form were also excluded from the trial.

**Design of experiment**

A total of 250 patients were subjected to simple randomization (1:1 ratio). All the patients have been treated identically before the trial. Prefilled envelopes were used for the purpose of randomization. The physicians involved in the randomization were not involved in the treatment. The sample size was calculated using OpenEpi 3.01-English (Open Source Epidemiologic Statistics for Public Health, Los Angeles, USA). The sample size was found to be 125 for both groups. The other factors, two-sided confidence intervals were 80%, the outcome in both groups was 95% ($\alpha = 0.05$), the risk ratio detected was 1, and the normal approximation was 9.917%. The flow diagram of the study is presented in Fig. 1.

**Intervention**

As first-line therapy, patients of IFN-α group received subcutaneous 9 × 10^6 IU/m^2 IFN-α at every 21 days for 4 months [1]. Patients of IL-2 group received continuous (over 96 h) intravenous 9 × 10^6 IU/m^2 IL-2 at every 21 days for 4 months [14].

---

**Table 1** Demographic characteristics of the enrolled patients

| Intervention | IFN-α (n = 125) | IL-2 (n = 125) | Comparison between groups (P value) |
|--------------|----------------|---------------|----------------------------------|
| Sex          |                |               |                                  |
| Male         | 86 (69)        | 81 (65)       | 0.591                            |
| Female       | 39 (31)        | 44 (35)       |                                  |
| Age (years)  | Minimum        |               |                                  |
|              | 20             | 21            | 0.072                            |
|              | Maximum        | 62            | 61                               |
|              | Average        | 4752 ± 3.52   | 44.15 ± 4.45                     |
| ECOG status  | 0              | 75 (60)       | 71 (57) 0.267                    |
|              | 1              | 49 (39)       | 53 (42)                          |
|              | 2              | 01 (1)        | 01 (1)                           |
| Type of melanoma |          |               |                                  |
| Cutaneous    | 97 (77)        | 95 (76)       | 0.366                            |
| Mucosal      | 13 (10)        | 16 (13)       |                                  |
| Acral lentiginous | 15 (13)       | 14 (11)       |                                  |
| Stage of unresectable melanoma |          |               |                                  |
| IIA          | 27 (22)        | 32 (26)       | 0.71                             |
| IIIB         | 3 (2)          | 2 (2)         |                                  |
| IIIIC        | 95 (76)        | 91 (72)       |                                  |
| Lactate dehydrogenase level |          |               |                                  |
| Normal       | 102 (82)       | 99 (79)       | 0.229                            |
| Above normal | 23 (18)        | 26 (21)       |                                  |
| Lymph node status |          |               |                                  |
| ≥4           | 19 (15)        | 14 (11)       | 0.35                             |
| 2–3          | 37 (30)        | 31 (25)       |                                  |
| 1            | 69 (55)        | 80 (64)       |                                  |
| Ulceration of primary lesions |          |               |                                  |
| No           | 71 (57)        | 76 (61)       | 0.61                             |
| Yes          | 54 (43)        | 49 (39)       |                                  |
| Breslow thickness/Clark number |          |               |                                  |
| <1           | 75 (60)        | 69 (55)       | 0.22                             |
| 1–2          | 25 (20)        | 31 (25)       |                                  |
| 2.01–4       | 15 (12)        | 21 (17)       |                                  |
| >4           | 10 (8)         | 04 (8)        |                                  |
| Primary site |                |               |                                  |
| Lower extremity | 28 (22)       | 23 (19)       | 0.68                             |
| Head         | 19 (16)        | 21 (17)       |                                  |
| Neck         | 20 (16)        | 14 (11)       |                                  |
| Upper extremity | 29 (23)       | 33 (26)       |                                  |
| Trunk        | 29 (23)        | 34 (27)       |                                  |

Continuous parameters reported as mean ± SD and constant parameters reported as n (%). ECOG, Eastern Cooperative Oncology Group performance (0: fully active, 1: carry out work with light nature, 2: capable of all self-care but not able to perform work activities, 3: capable of only limited self-care, 4: completely disabled, 5: dead); IFN, interferon; IL, interleukin; RECIST, Response Evaluation Criteria in Solid Tumors. Repeated measures analysis of variance was used for continuous data and the $\chi^2$ independence test was used for constant data.

$^a$RECIST v1.1.

$^b$Normal level: 140–333 IU/L.

$^c$The total vertical height of the melanoma.
Response evaluation
The Response Evaluation Criteria in Solid Tumors v1.1 guideline was used for evaluation of disease progression and tumor response [15]. The computed tomography of the pelvis, abdomen, and the chest and MRI of the brain were used to assess the treatment response. Times to tumor progression were considered from the time of intervention initiation to proof of tumor progression. Overall survival was considered from the time of detection of malignant melanoma to the death [14].

Treatment-emergent adverse effects
The US National Cancer Institute’s Common Terminology Criteria for Adverse Events v4.0 were used for evaluation of toxicity [16]. Patients subjected to an anatomical characterization and laboratory tests. Lactate dehydrogenase (lactate dehydrogenase test), complete metabolic panel (blood and urine glucose level, blood sodium, blood potassium, blood carbon dioxide, blood chloride levels, and liver function test), and complete blood count (red blood cell count, hemoglobin, white blood cell count,
and platelet count) during and before every cycle were evaluated [14].

**Cost of treatment**
The purpose of calculating the cost in the study was to check the need for financial help for treatment to patients or not. Cost of treatment was included in the cost of diagnosis, interventions, healthcare management, and expert charges. The cost was considered from the time of detection of malignant melanoma to the death.

**Statistical analysis**
InStat (version Window; GraphPad, Indiana, San Diego, California, USA) was used for statistical analysis. Repeated measures analysis of variance was used for continuous data and the χ²-independence test was used for constant data. Results were considered significant at 95% of confidence level. Intention-to-treat method of analysis was adopted.

**Results**
Radiographic images concluded that after 4 months, patients of both groups had an absence of brain, lung, heart, and liver metastases in the patients who had no brain, lung, heart, and liver metastases before treatment. Even if brain metastasis was present at the time of enrollment (Fig. 2a), IL-2 was effective to improve brain metastasis after 4 months of intervention (Fig. 2b). However, IFN-α failed to improved metastasis after 4 months of intervention.
Compared with before treatment (Fig. 3a), IL-2 was effective in improving malignant melanoma after 4 months of intervention (Fig. 3b). In a similar manner, as compared with before treatment (Fig. 4a) IFN-α was also effective in improving malignant melanoma after 4 months of intervention (Fig. 4b).

The overall survival was counted up to 800 days of the follow-up period, and progression-free survival was counted up to 500 days of the follow-up period. Patients of the IL-2 group had a higher overall survival ($P < 0.0001$; Fig. 5) and a higher progression-free survival ($P = 0.002$; Fig. 6) than those of IFN-α group.

Hypotension, kidney dysfunction, and liver dysfunctions were major continuous intravenous IL-2-emergent adverse effects. Thrombocytopenia and neutropenia were major subcutaneous IFN-α-emergent adverse effects (Table 2).

Continuous intravenous IL-2 caused flu-like symptoms (chills, muscle pain, and fever) and capillary leak syndrome (systemic edema, pulmonary edema, weight gain, ascites, and pleural effusion; Table 3).

Healthcare management and expert charges lead to increase in the cost of treatment for IL-2 group than IFN-α group (total cost of therapy: 105 345 ± 9845 ¥/patient vs. 95 656 ± 7586 ¥/patient, $P < 0.0001$; Fig. 7).

**Discussion**

In the study, subcutaneous IFN-α or continuous (dripping over 96 h) intravenous IL-2 as a first-line therapy in patients with malignant melanoma was preferred instead of using a chemotherapeutic agent(s). The chemotherapeutic agents used in malignant melanoma like cisplatin induce thrombocytopenia, acute renal failure, and peripheral neuropathy [14].
Vinca alkaloids and nab-paclitaxel induce neurotoxicity and neutropenia [17]. Docetaxel and carboplatin have adverse effects like neutropenia, anemia, and thrombocytopenia [18]. Fresolimumab may develop hyperkeratosis [19] and squamous cell carcinomas [20]. Moreover, combination therapies of chemotherapeutic agent(s) with IFN-α or IL-2 may have somewhat higher tumor response but have severe toxicities and the less overall survival of the patients [17]. IFN-α has immunoregulatory, antiangiogenic, antiproliferative, differentiation-inducing, and proapoptotic effects [21]. IL-2 is a natural part of the immune system. It is a messenger molecule (cytokine) that is secreted from 10^6 IU/m²/day (low dose) of IL-2 is not effective and its high dose (100–150 × 10^6 IU/m²/day) is toxic [8]. 700 × 10^6 IU/m²/week subcutaneous administration of IL-2 is less toxic than 100 × 10^6 IU/m²/day intravenous infusion but more toxic than 9 × 10^6 IU/m²/3-week dripping over 96 h [4]. Overall survival irrespective of disease conditions is higher for patients who received subcutaneous IFN-α than those who

![Progression-free survival of patients.](image.png)

**Table 2 Hematological treatment-emergent adverse effects after 4 months from the time of intervention initiation**

| Groups | IFN-α (n = 125) | IL-2 (n = 125) | Comparison between groups (P value*) |
|--------|----------------|----------------|-----------------------------------|
| Intervention | Subcutaneous interferon-α | Continuous intravenous interleukin-2 |                                |
| Hypotension | 3 (2) | 40 (32) | <0.0001 |
| Liver dysfunctionb | 2 (2) | 35 (28) | <0.0001 |
| Kidney dysfunctionc | 2 (2) | 17 (14) | 0.0008 |
| Neutropeniaf | 39 (31) | 5 (4) | <0.0001 |
| Anemia | 7 (6) | 7 (6) | NA |
| Lymphopenia | 2 (2) | 3 (2) | 0.651 |

Data are represented as n (%). The χ²-independence test was used for statistical analysis. IFN, interferon; IL, interleukin; NA, not applicable.

*Significant continuous intravenous interleukin-2-emergent adverse effects.
*Significant subcutaneous interferon-α-emergent adverse effects.
^Serum creatinine > 1.8 mg/dl.
^Absolute neutrophil count 300 cells/ml.
*P < 0.05 was considered significant.

**Table 3 Nonhematological treatment-emergent adverse effects after 4 months from the time of intervention initiation**

| Groups | IFN-α (n = 125) | IL-2 (n = 125) | Comparison between groups (P value*) |
|--------|----------------|----------------|-----------------------------------|
| Intervention | Subcutaneous interferon-α | Continuous intravenous interleukin-2 |                                |
| Diarrhea | 5 (4) | 7 (6) | 0.767 |
| Nausea | 3 (2) | 4 (3) | 0.701 |
| Fatigue | 10 (3) | 3 (2) | 0.087 |
| Headache | 4 (3) | 5 (4) | 0.734 |
| Skin rash | 1 (1) | 1 (1) | NA |
| Constipation | 3 (2) | 2 (2) | 0.651 |
| Pruritus | 1 (1) | 0 (0) | 0.316 |
| Neurophy | 1 (1) | 1 (1) | NA |
| Taste alteration | 1 (1) | 1 (1) | NA |
| Vomiting | 4 (3) | 3 (2) | 0.701 |
| Flu-like symptomb | 1 (1) | 11 (9) | 0.008 |
| Capillary leak syndromea | 2 (2) | 3 (2) | 0.651 |
| Rhabdomyolysis | 0 (0) | 4 (3) | 0.0008 |

Data are represented as n (%). The χ²-independence test was used for statistical analysis. IFN, interferon; IL, interleukin; NA, not applicable.

*Significant continuous intravenous interleukin-2-emergent adverse effects.
^Systemic edema, pulmonary edema, weight gain, ascites, and pleural effusion.
*P < 0.05 was considered significant.
received the same dose of continuous IFN-α [22]. With respect to the regimen selected in the study for patients, the researchers justified interventions to improve overall survival and quality of life with or without disease activity of patients.

The trial was performed with IL-2 and IFN-α for six cycles only at the interval of 21 days. Previous studies have reported that administration of IFN-α for short period (4 weeks) and long period (1 year) has the same relapse-free survival in White patients [1,23] and administration of IL-2 for a longer period of time is not tolerated by patients [4,24]. With respect to interventions of the subjects, the trial was designed so that they achieve maximum response with minimum toxicities.

After 4 months, patients of both groups had an absence of brain, lung, heart and liver metastases. However, kidney and liver dysfunctions and hypotension were reported in the patients who had received continuous intravenous IL-2. IL-2 has cardiovascular toxicities [9]. Continuous intravenous IL-2 has urogenital and hepatic adverse effects [4,25]. Even patients of the IL-2 group had flu-like symptoms and capillary leak syndrome as measured by nonhematological adverse effects. Hypovolemia owing to capillary leak syndrome may reduce blood perfusion in the brain, resulting in dysfunction of the body [4]. However, low dose of IFN-α (intravenous $10^6$ IU/m$^2$) has only flu-like symptoms, nausea, and nonhematological adverse effects [26]. In considering the adverse effects of the study, subcutaneous IFN-α is the reasonable treatment option for patients with malignant melanoma but Chinese guidelines for treatment of malignant melanoma has not recommended low and medium doses of subcutaneous IFN-α because it does not improve the survival, and there is no experience of using higher subcutaneous dose ($10^6$ IU/m$^2$/3 weeks) of IFN-α in Chinese patients [4]. Therefore, Chinese guidelines for treatment of malignant melanoma are required to update in terms of adjuvant treatment of malignant melanoma.

The treatment with subcutaneous IFN-α was cheaper than continuous intravenous IL-2 but had less overall survival and less progress-free survival. Subcutaneous IFN-α has no significant effects as compared with placebo [4,27,28] but has better response in ulcerated primary melanoma [29]. Subcutaneous IFN-α could be recommended in relapse-free patients.

There were several limitations of the study, for examples, the results of the study were applicable to Chinese patients only. The effects of demographic characteristics on the response were not evaluated. Measures used to control adverse effects were not evaluated. The effects of measures to maintain toxic effects on overall survival and quality of life of patients were not discussed. The blinded procedure has more reliable results, but in the study, blinding was not possible. The change in immune cells and other cell types and their effect/role in disease progression and tumor response were not examined.

**Conclusion**

Subcutaneous IFN-α is a safer option than continuous intravenous IL-2 in patients with malignant melanoma. However, the good response may be reported in continuous intravenous IL-2 in short treatment period with moderate adverse effects.

**Acknowledgements**

Authors are thankful for the medical, pathological, radiological, and other nonmedical staff of Cancer Hospital of China Medical University, Shenyang, China; Ross University School of Medicine, Miramar, Florida, USA; and the Graduate School, China Medical University, Shenyang, China.

The funding for the treatment was done by the patients themselves.

Authors’ contributions: All contributing authors listed on the manuscript are aware of and agree to the submission of this manuscript. S.L. and X.W. equally contributed to the conceptualization, the design, and formal analysis of the study. P.C. was the project administrator and contributed to visualization and the design of the study. Y.P. contributed to the conceptualization, data curation, supervision, and validation of the study. K.Z. contributed to the design, resources, and investigation for the study. W.W. contributed to the methodology, resources, and software for the study. E.Q. contributed to the conceptualization, data curation, formal analysis, and supervision of the study. X.Z. contributed to the conceptualization, data curation, and the draft and edited the manuscript for intellectual content. The authors agree to be accountable for all aspects of work ensuring integrity and accuracy.
Availability of data and materials: The datasets used and analyzed during the current study were available from the corresponding authors on reasonable request.

Conflicts of interest
There are no conflicts of interest.

References

1. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, et al. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon-α-2b in high-risk acral melanoma patients. *Eur J Cancer* 2011; 47:1498–1503.
2. Heise R, Amann PM, Ensslen S, Marquardt Y, Czaja K, Jousset S, et al. Interferon-alpha signaling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. *PLoS One* 2016; 11:e0148325.
3. Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? *Curr Oncol* 2009; 16:3–6.
4. Guo J, Qin S, Liang J, Lin T, Si L, Chen X, et al. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). *Clin Chin Oncol* 2016; 5:57.
5. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. *Annu Rev Immunol* 2005; 23:307–336.
6. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. *J Natl Cancer Inst* 2010; 102:493–501.
7. Moschos S, Kirkwood JM. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. *Cytokine Growth Factor Rev* 2007; 18:451–458.
8. Koreth J, Ritz J, Tsokos GC, Pugliese A, Malek TR, Rosenzwajg M, et al. Low-dose Interleukin-2 in the treatment of autoimmune disease. *Oncology & Hematology Review* 2014; 10:157–163.
9. Bi-xia T, Lu S, Zh-hong C, Chuan-liang C, Xin-nan S, Li-li M, et al. A phase II clinical trial of recombinant human interferon-α-2b in treatment of advanced melanoma. *Tumor* 2011; 31:1042–1046.
10. Kirkwood JM, Tarhini AA, Moschos SJ, Panelli MC. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIb/III melanoma. *Nat Clin Pract Oncol* 2008; 5:2–3.
11. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010; 63:e1–e37.
12. World Medical Association. Declaration of Helsinki: ethical principles for Medical research involving human subjects 64th WMA General Assembly, World Medical Association Inc., Fortaleza, Brazil. 2013.
13. ECOG Performance Status. Available at: http://www.ncrcc.org/files/news/ECOG_performance_status.pdf. [Accessed 1 January 2015].
14. Airwas A, Papadopoulos NE, Cai S, Patel SP, Kim KB, Deburr TL, et al. Phase I trial of biochemistry with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. *Melanoma Res* 2014; 24:342–348.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2000; 49:228–247.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2018. Available at: https://cdepcancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_4.03.pdf. [Accessed 18 October 2018].
17. Bhattach S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview. *Oncology* 2009; 23:498–494.
18. Lee CK, Jung M, Choi HI, Kim HR, Kim HS, Roh MR, et al. Results of a phase II study to evaluate the efficacy of Docetaxel and Carboplatin in metastatic malignant melanoma patients who failed first-line therapy containing dacarbazine. *Cancer Res Treat* 2015; 47:781–789.
19. Morris JC, Tan AR, Olenczi TE, Shapiro GI, Dezube BJ, Reiss M, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody and continuous infusion in patients with advanced malignant melanoma or renal cell carcinoma. *PLoS One* 2014; 9:e90393.
20. Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, et al. A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. *Kidney Int Rep* 2017; 2:800–810.
21. Tarhini AA, Gogas H, Kirkwood JM. IFN-α in the treatment of melanoma. *J Immunol* 2012; 189:83789–83793.
22. Ravaud A, Delva R, Gomez F, Chevreau C, Douillard JY, Peny J, et al. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma: Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Francais d’Immunotherapie. *Cancer* 2002; 95:2324–2330.
23. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. *J Clin Oncol* 2009; 27:939–944.
24. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008; 14:5610–5618.
25. Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. *Brit J Cancer* 2004; 90:1156–1162.
26. Ravaud A, Bedane C, Geoffrois L, Lesimple T, Delauzay M. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. *Br J Cancer* 1999; 80:1767–1769.
27. Eggermont AM, Suciu S, Mackie R, Ruka W, Testori A, Kruit W, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa-2b versus observation in patients with stage IIIb/III melanoma (EORTC 18952): Randomised controlled trial. *Lancet* 2005; 366:1189–1196.
28. Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, et al. Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2SNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). *J Clin Oncol* 2017; 35:885–892.
29. Eggermont AM, Suciu S, Testori A, Patel P, Spatz A. Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2644 patients. *J Clin Oncol* 2009; 27:9007.